Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Non-Current Assets data on record, last reported at $60.4 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 37.13% year-over-year to $60.4 million; the TTM value through Dec 2025 reached $273.8 million, up 19.53%, while the annual FY2025 figure was $60.4 million, 37.13% down from the prior year.
  • Non-Current Assets reached $60.4 million in Q4 2025 per APLS's latest filing, down from $68.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $96.1 million in Q4 2024 and bottomed at $20.5 million in Q1 2024.
  • Average Non-Current Assets over 5 years is $47.5 million, with a median of $43.5 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: tumbled 47.63% in 2023, then skyrocketed 329.02% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $57.7 million in 2021, then dropped by 29.5% to $40.7 million in 2022, then crashed by 44.96% to $22.4 million in 2023, then surged by 329.02% to $96.1 million in 2024, then plummeted by 37.13% to $60.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $60.4 million in Q4 2025, $68.0 million in Q3 2025, and $65.8 million in Q2 2025.